Institute for Clinical & Economic Review to Postpone Assessment of Gene Therapy for Beta Thalassemia
March 04, 2020
March 04, 2020
BOSTON, Massachusetts, March 4 -- The Institute for Clinical and Economic Review issued the following announcement:
The Institute for Clinical and Economic Review (ICER) announced that we plan to postpone our ongoing assessment of LentiGlobin (bluebird bio) for the treatment of beta thalassemia.
Once a clearer timeframe for the therapy's FDA review is known, we will reinitiate this assessment and announce an updated timeframe, which will include a new date for our . . .
The Institute for Clinical and Economic Review (ICER) announced that we plan to postpone our ongoing assessment of LentiGlobin (bluebird bio) for the treatment of beta thalassemia.
Once a clearer timeframe for the therapy's FDA review is known, we will reinitiate this assessment and announce an updated timeframe, which will include a new date for our . . .